Genetic variants in TNF-alpha promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy
机构:[1]Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX[2]Department of Otorhinolaryngology-Head and Neck Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China[3]Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX[4]Department of Otolaryngology-Head and Neck Surgery, Yuhuangding Hospital of Qingdao University, Yantai, China[5]Division of Biostatistics and Human Genetics Center, University of Texas School of Public Health, Houston, TX[6]Department of Stomatology, Jinling Hospital, School of Medicine, Nanjing University, Southern Medical University, Nanjing, China[7]Department of Head and Neck Surgery, Sichuan Cancer Hospital, Chengdu, China外科中心头颈外科中心四川省肿瘤医院头颈外科
The promoter variants of TNF-, a major regulator of immune and inflammation responses, have been implicated in cancer development and prognosis. Thus, we investigated associations between four TNF- promoter variants and risk of recurrence of squamous cell carcinoma of the oropharynx (SCCOP). We evaluated associations of four TNF- polymorphisms with risk of recurrence in a cohort of 846 patients with SCCOP. Log-rank test and multivariable Cox models were used to evaluate associations. Compared with patients with variant genotypes of the TNF- -308 and TNF- -863 polymorphisms, patients with common homozygous genotypes had worse disease-free survival (log-rank p = 0.0002 and p < 0.0001, respectively) and increased risk of SCCOP recurrence (HR, 1.9, 95% CI, 1.3-2.8 and HR, 1.9, 95% CI, 1.3-2.7, respectively) after multivariable adjustment. Furthermore, among patients with HPV16-positive tumors, those with common homozygous genotypes of the TNF- -308 and -863 polymorphisms had worse disease-free survival (log-rank p = 0.005 and p = 0.007, respectively) and higher recurrence risk than patients with variant genotypes of these polymorphisms (HR, 5.1, 95% CI, 1.4-18.4 and HR, 3.7, 95% CI, 1.5-9.1, respectively), while no such significant associations were found for TNF- -857 or -1031 polymorphisms. Our findings suggest that TNF- -308 and -863 polymorphisms may modulate the risk of SCCOP recurrence in patients with HPV16-positive tumors. However, larger studies are needed to validate these results.
基金:
NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 ES011740, CA128110-01A1, CA135679, CA133099]
第一作者机构:[1]Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX[2]Department of Otorhinolaryngology-Head and Neck Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX[3]Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX[*1]Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1445, Houston, Texas 77030-4009, USA
推荐引用方式(GB/T 7714):
Zhang Caiyun,Sturgis Erich M.,Zheng Hongliang,et al.Genetic variants in TNF-alpha promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy[J].INTERNATIONAL JOURNAL OF CANCER.2014,134(8):1907-1915.doi:10.1002/ijc.28512.
APA:
Zhang, Caiyun,Sturgis, Erich M.,Zheng, Hongliang,Song, Xicheng,Wei, Peng...&Li, Guojun.(2014).Genetic variants in TNF-alpha promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy.INTERNATIONAL JOURNAL OF CANCER,134,(8)
MLA:
Zhang, Caiyun,et al."Genetic variants in TNF-alpha promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy".INTERNATIONAL JOURNAL OF CANCER 134..8(2014):1907-1915